Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

423
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
423
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

813
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
813
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

695
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
695
Factors Affecting Protein-Drug Binding: Drug Interactions01:23

Factors Affecting Protein-Drug Binding: Drug Interactions

727
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
727
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

379
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
379

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

LDL-cholesterol distance to target: A practical tool for guiding lipid-lowering treatment decisions.

Atherosclerosis plus·2026
Same author

Corrigendum to "Heated tobacco product aerosol emission compared to cigarette smoke: A scoping review" [Toxicol. Rep. 16 (2026) 102209].

Toxicology reports·2026
Same author

Are we underestimating the benefits of lipid-lowering therapies?

Pharmacological reviews·2026
Same author

Hemostatic Aspects of Interactions Between Anticancer Drugs and Oral Anticoagulants in Patients with Cancer-Associated Venous Thromboembolism.

Seminars in thrombosis and hemostasis·2026
Same author

New frontiers in the treatment of hypercholesterolaemia: oral inhibition of PCSK9.

European heart journal supplements : journal of the European Society of Cardiology·2026
Same author

Fragility Analysis of Cardiovascular Outcomes with Finerenone in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.

European journal of heart failure·2026

Related Experiment Video

Updated: May 4, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K

Drug-drug interaction with statins.

Alberto Corsini1, Stefano Bellosta

  • 1University of Milan, Department of Pharmacological Sciences, via Balzaretti 9, 20133 Milan, Italy. alberto.corsini@unimi.it.

Expert Review of Clinical Pharmacology
|January 14, 2014
PubMed
Summary

Statins, or 3-hydroxy-3-methyl-glutaryl (HMG)-CoA reductase inhibitors, are effective for high cholesterol. This review highlights their pharmacokinetic properties and clinically significant drug interactions.

Area of Science:

  • Pharmacology
  • Drug Interactions
  • Cardiovascular Medicine

Background:

  • Statins (HMG-CoA reductase inhibitors) are primary treatments for hypercholesterolemia.
  • Statin monotherapy is generally safe with infrequent adverse events like myopathy or elevated transaminases.
  • Long-term statin use necessitates attention to drug-drug interactions due to polypharmacy.

Purpose of the Study:

  • To review the pharmacokinetic properties of statins.
  • To emphasize clinically relevant drug interactions associated with statin therapy.

Main Methods:

  • Literature review of pharmacokinetic properties of statins.
  • Analysis of reported drug-drug interactions involving statins.

Main Results:

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.2K
Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

21.0K

Related Experiment Videos

Last Updated: May 4, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.2K
Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

21.0K
  • Statins exhibit variable pharmacokinetic profiles.
  • Clinically significant interactions can alter statin efficacy and safety.
  • Concomitant use with other lipid-lowering agents or drugs for comorbidities requires careful consideration.

Conclusions:

  • Understanding statin pharmacokinetics is crucial for managing drug interactions.
  • Drug interactions are a key factor in the overall safety profile of statins.
  • This review provides essential information for healthcare professionals managing patients on statin therapy.